CDKN2B and colorectal carcinoma: Furthermore, our analysis revealed that differentially expressed lncRNAs (e.g., CDKN2B-AS1 and TMEM220-AS1) may function as epigenetic regulators in CRC pathogenesis, opening new avenues for RNA-targeted therapies [32].